Relation between estradiol and negative symptoms in men with schizophrenia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 17, Issue 2, 2005, Pages 239-242

  Kaneda, Y ^a   Ohmori, T ^b  

^a TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; ESTRADIOL; OLANZAPINE; PEROSPIRONE; QUETIAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ESTRADIOL BLOOD LEVEL; HUMAN; MALE; NEGATIVE SYNDROME; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; HOSPITAL PATIENT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; ESTRADIOL; HUMANS; INPATIENTS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 85047690794     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.17.2.239     Document Type: Article

References (14)

1. Rao ML, Kolsch H: Effects of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia (1). Psychoneuroendocrinol 2003; 28 (Suppl 2):83-96
2. Riecher-Rössler A: Oestrogen effects in schizophrenia and their potential therapeutic implications-review. Arch Women Ment Health 2002; 5:111-118
3. Moriarty PJ, Lieber D, Bennett A, et al: Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull 2001; 27:103-113
4. Kulkarni J, Riedel A, de Castella AR, et al: Estrogen-a potential treatment for schizophrenia. Schizophr Res 2001; 48:137-144
5. Lindamer LA, Buse DC, Lohr JB, et al: Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 2001; 49:47-51
6. Gattaz WF, Vogel P, Riecher-Rossler A, et al: Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry 1994; 36:137-139
7. Kaneda Y, Kawamura I, Fujii A, et al: Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia drugs (Japanese version). Rinsyo Seisin Yakuri Jpn J Clin Psychopharmacol, 2004; 7:483-492.
8. Kaneda Y, Kawamura I, Fujii A, et al: Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia drugs (English version). Neuroendocrinol Lett, 2004; 25:135-140.
9. Inagaki A, Inada T, Fujii Y, et al: Dose equivalence of psychotropic drugs (in Japanese). Tokyo, Seiwa Shoten Co., Ltd., 1999
10. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC, American Psychiatric Association, 1994
11. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
12. Guy W (ed.): ECDEU Assessment Manual for Psychopharmacology (publication ADM 76-338). Washington, DC, US Department of Health, Education, and Welfare, 1976
13. Riecher-Rössler A, Hafner H, Stumbaum M, et al: Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994; 20:203-214
14. Franks S, Jacobs HS, Martin N, et al: Hyperprolactinaemia and impotence. Clin Endocrinol (Oxf) 1978; 8:277-287